|
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
87 gevonden resultaten
| nr | titel | auteur | tijdschrift | jaar | jaarg. | afl. | pagina('s) | type |
| 1 | A fresh look at pharmaceutical screening library design |
Nilakantan, Ramaswamy |
2003 |
15 |
p. 668-672 5 p. |
artikel |
||
| 2 | An everlasting flu vaccine with none of the pain |
Thacker, Paul D |
2003 |
15 |
p. 660-661 2 p. |
artikel |
||
| 3 | Animal models and human genome diversity: the pitfalls of inbred mice |
Gurwitz, David |
2001 |
15 |
p. 766-768 3 p. |
artikel |
||
| 4 | A novel nasal nicotine formulation for smoking cessation |
Weidner, John |
2002 |
15 |
p. 833-835 3 p. |
artikel |
||
| 5 | A quiet revolution in lead optimisation services? |
Cavalla, David |
2004 |
15 |
p. 635-636 2 p. |
artikel |
||
| 6 | Bioassays – a continuously developing field |
Robinson, Jane |
2003 |
15 |
p. 676-678 3 p. |
artikel |
||
| 7 | Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer |
Hofmann, Francesco |
2005 |
15 |
p. 1041-1047 7 p. |
artikel |
||
| 8 | Bob Ruffolo discusses the rhythm of drug development |
Ruffolo, Bob |
2004 |
15 |
p. 631-635 5 p. |
artikel |
||
| 9 | Cancer drug delivery is hot stuff |
Habeck, Martina |
2001 |
15 |
p. 754-756 3 p. |
artikel |
||
| 10 | CDK inhibitor shows promise for inflammatory kidney disease |
Clough, Joanne |
2002 |
15 |
p. 789-790 2 p. |
artikel |
||
| 11 | Cell cycle inhibitors key to neoangiogenesis |
Sutherland, Stephani |
2005 |
15 |
p. 1015-1016 2 p. |
artikel |
||
| 12 | Chemoproteomics as a basis for post-genomic drug discovery |
Beroza, Paul |
2002 |
15 |
p. 807-814 8 p. |
artikel |
||
| 13 | Clinical genomics comes of age |
Wortman, Marc |
2003 |
15 |
p. 678-680 3 p. |
artikel |
||
| 14 | Combinatorial chemistry |
Edwards, Paul |
2001 |
15 |
p. 810-811 2 p. |
artikel |
||
| 15 | Data management solutions for protein therapeutic research and development |
Vielmetter, Jost |
2005 |
15 |
p. 1065-1071 7 p. |
artikel |
||
| 16 | De novo chemical ligand design ▾ |
Chan, Ting-Fung |
2002 |
15 |
p. 802-803 2 p. |
artikel |
||
| 17 | Drug delivery |
Weidner, J |
2002 |
15 |
p. 832-833 2 p. |
artikel |
||
| 18 | Drug delivery |
Weidner, John |
2001 |
15 |
p. 809-810 2 p. |
artikel |
||
| 19 | Drug-free tolerance of transplanted tissue |
Whelan, Jo |
2001 |
15 |
p. 756-757 2 p. |
artikel |
||
| 20 | Economics, pharmacoeconomics and drug discovery for dementias |
Fillit, Howard |
2002 |
15 |
p. 785-787 3 p. |
artikel |
||
| 21 | Electrifying new treatment for epilepsy |
Fricker, Janet |
2001 |
15 |
p. 757-758 2 p. |
artikel |
||
| 22 | Embryonic Stem Cells: Methods and Protocols |
Paul, Gesine |
2002 |
15 |
p. 806- 1 p. |
artikel |
||
| 23 | EuroBiochips: spot the difference! |
Soloviev, Mikhail |
2001 |
15 |
p. 775-777 3 p. |
artikel |
||
| 24 | Fighting superbugs with superdrugs |
Carey, Jayne |
2004 |
15 |
p. 637-640 4 p. |
artikel |
||
| 25 | First clinical data on RNAi |
Whelan, Jo |
2005 |
15 |
p. 1014-1015 2 p. |
artikel |
||
| 26 | From magic bullets to designed multiple ligands |
Morphy, Richard |
2004 |
15 |
p. 641-651 11 p. |
artikel |
||
| 27 | Gene therapy trials for cystic fibrosis |
Brown, Matt |
2002 |
15 |
p. 788-789 2 p. |
artikel |
||
| 28 | Gene therapy versus protein-based therapy: a matter of pharmacokinetics |
Post, Mark J. |
2001 |
15 |
p. 769-770 2 p. |
artikel |
||
| 29 | Hitting the chemotherapy jackpot: strategy, productivity and chemistry |
Westwell, Andrew D. |
2004 |
15 |
p. 625-627 3 p. |
artikel |
||
| 30 | How can we avoid the productivity gap? |
Carney, Steve |
2005 |
15 |
p. 1011-1013 3 p. |
artikel |
||
| 31 | How many genomics targets can a portfolio afford? |
Betz, Ulrich A.K. |
2005 |
15 |
p. 1057-1063 7 p. |
artikel |
||
| 32 | 17β-Hydroxysteroid dehydrogenase inhibitors; thrombin receptor (PAR-1) antagonists |
Edwards, Paul |
2002 |
15 |
p. 831-832 2 p. |
artikel |
||
| 33 | Keynote review: Is declining innovation in the pharmaceutical industry a myth? |
Schmid, Esther F. |
2005 |
15 |
p. 1031-1039 9 p. |
artikel |
||
| 34 | Macroresults through Microarrays |
Rockett, John C |
2002 |
15 |
p. 804-805 2 p. |
artikel |
||
| 35 | Medicinal chemistry of target family-directed masterkeys |
Müller, Gerhard |
2003 |
15 |
p. 681-691 11 p. |
artikel |
||
| 36 | Modelling and simulation in clinical drug development |
Rooney, Kieran F. |
2001 |
15 |
p. 802-806 5 p. |
artikel |
||
| 37 | Modified release drug delivery in veterinary medicine |
Rathbone, Michael J |
2002 |
15 |
p. 823-829 7 p. |
artikel |
||
| 38 | Molecular diversity through sugar scaffolds |
Thanh Le, Giang |
2003 |
15 |
p. 701-709 9 p. |
artikel |
||
| 39 | Molecules |
Edwards, Paul |
2003 |
15 |
p. 717-718 2 p. |
artikel |
||
| 40 | Monitor – biology |
Heath, Victoria |
2004 |
15 |
p. 678-681 4 p. |
artikel |
||
| 41 | Monitor – biology |
Collin, Mattias |
2005 |
15 |
p. 1073- 1 p. |
artikel |
||
| 42 | Monitor – business |
Carey, Jayne |
2004 |
15 |
p. 681-682 2 p. |
artikel |
||
| 43 | Monitor – chemistry |
Edwards, Paul |
2004 |
15 |
p. 677-678 2 p. |
artikel |
||
| 44 | Monitor – chemistry |
Sivaprakasam, Kannan |
2005 |
15 |
p. 1072- 1 p. |
artikel |
||
| 45 | Monitor: molecules and profiles |
Walker, Michael A |
2002 |
15 |
p. 830-831 2 p. |
artikel |
||
| 46 | Monitor: molecules and profiles |
Barlocco, Daniela |
2001 |
15 |
p. 807-809 3 p. |
artikel |
||
| 47 | Monitor – people |
Carey, Jayne |
2004 |
15 |
p. 682- 1 p. |
artikel |
||
| 48 | Neuroprotection in stroke: is it time to consider large-molecule drugs? |
Pardridge, William M. |
2001 |
15 |
p. 751-753 3 p. |
artikel |
||
| 49 | New ray of hope for cancer patients |
Habeck, Martina |
2004 |
15 |
p. 630- 1 p. |
artikel |
||
| 50 | News in Brief |
Brown, Matt |
2003 |
15 |
p. 662-664 3 p. |
artikel |
||
| 51 | News in brief |
Brown, Matt |
2002 |
15 |
p. 792-795 4 p. |
artikel |
||
| 52 | News in brief |
Lawrence, R.N. |
2001 |
15 |
p. 759-762 4 p. |
artikel |
||
| 53 | Novel antitumour molecules |
Westwell, Andrew D |
2003 |
15 |
p. 718-719 2 p. |
artikel |
||
| 54 | Novel candidate for treatment of haematopoietic disorders |
Foubister, Vida |
2003 |
15 |
p. 659-660 2 p. |
artikel |
||
| 55 | Novel proteases for drug discovery |
Moss, Marcia |
2001 |
15 |
p. 770- 1 p. |
artikel |
||
| 56 | Optimizing the discovery organization for innovation |
Sams-Dodd, Frank |
2005 |
15 |
p. 1049-1056 8 p. |
artikel |
||
| 57 | Organizing the organization |
Peakman, Tim |
2003 |
15 |
p. 673- 1 p. |
artikel |
||
| 58 | Parasite movement: crucial anchor revealed |
Carey, Jayne |
2004 |
15 |
p. 629-630 2 p. |
artikel |
||
| 59 | People |
Brown, Matt |
2002 |
15 |
p. 796- 1 p. |
artikel |
||
| 60 | People |
Owens, Joanna |
2003 |
15 |
p. 665- 1 p. |
artikel |
||
| 61 | People |
Lawrence, Rebecca N. |
2001 |
15 |
p. 763- 1 p. |
artikel |
||
| 62 | Personalia |
Demidov, Vadim V |
2003 |
15 |
p. 666-667 2 p. |
artikel |
||
| 63 | Personalia |
Demidov, Vadim V. |
2001 |
15 |
p. 764-765 2 p. |
artikel |
||
| 64 | Personalized cancer vaccine promises remission |
Sussman, Hillary E |
2003 |
15 |
p. 657-658 2 p. |
artikel |
||
| 65 | Peter Corr outlines Pfizer's approach to innovation, maximizing capabilities and delivering essential medicine |
Carney, Steve |
2005 |
15 |
p. 1017-1020 4 p. |
artikel |
||
| 66 | Pharmacogenomics suggests new treatment approach for leukaemia |
Senior, Kathryn |
2002 |
15 |
p. 791-792 2 p. |
artikel |
||
| 67 | Pharmacokinetic Optimization in Drug Research |
Pateman, Tony |
2001 |
15 |
p. 778- 1 p. |
artikel |
||
| 68 | Phospholipase A2 expression in tumours: a target for therapeutic intervention? |
Laye, Jonathan P |
2003 |
15 |
p. 710-716 7 p. |
artikel |
||
| 69 | Protein kinase drugs – optimism doesn't wait on facts ▾ |
Groom, Colin R |
2002 |
15 |
p. 801-802 2 p. |
artikel |
||
| 70 | Protein microarray technology |
Templin, Markus F. |
2002 |
15 |
p. 815-822 8 p. |
artikel |
||
| 71 | Proteomics: delivering new routes to drug discovery – Part 1 |
Jain, Kewal K. |
2001 |
15 |
p. 772-774 3 p. |
artikel |
||
| 72 | Question: what do you call 500 scientists coming together to address the productivity gap? Answer: a start |
Carney, Steve |
2005 |
15 |
p. 1025-1029 5 p. |
artikel |
||
| 73 | Receptor-mediated gene transfer by phage-display vectors: applications in functional genomics and gene therapy |
Larocca, David |
2001 |
15 |
p. 793-801 9 p. |
artikel |
||
| 74 | Resisting resistance |
Ewan, Scott |
2005 |
15 |
p. 1015- 1 p. |
artikel |
||
| 75 | Samir Hanash discusses how HUPO aims to globalize proteomics research |
Hanash, Samir |
2002 |
15 |
p. 797-801 5 p. |
artikel |
||
| 76 | Targeting the molecular mechanism of DNA replication |
Conti, Chiara |
2001 |
15 |
p. 786-792 7 p. |
artikel |
||
| 77 | Targeting tumors by necrosis |
Creavin, Treasa |
2004 |
15 |
p. 628- 1 p. |
artikel |
||
| 78 | The application of non-combinatorial chemistry to lead discovery |
Everett, Jeremy |
2001 |
15 |
p. 779-785 7 p. |
artikel |
||
| 79 | The future of antidepressants |
Learner, Frances |
2005 |
15 |
p. 1021-1024 4 p. |
artikel |
||
| 80 | The impact of cytochrome P450 allosterism on pharmacokinetics and drug–drug interactions |
Shou, Magang |
2004 |
15 |
p. 636-637 2 p. |
artikel |
||
| 81 | The secret lives of GPCRs |
Kenakin, Terry P. |
2003 |
15 |
p. 674- 1 p. |
artikel |
||
| 82 | Transgenic gene knockouts: a functional platform for the industry |
Sanseau, Philippe |
2001 |
15 |
p. 770-771 2 p. |
artikel |
||
| 83 | Ultrasound and transdermal drug delivery |
Lavon, Ilana |
2004 |
15 |
p. 670-676 7 p. |
artikel |
||
| 84 | Using probiotics and prebiotics to improve gut health |
Tuohy, Kieran M |
2003 |
15 |
p. 692-700 9 p. |
artikel |
||
| 85 | Utility of homology models in the drug discovery process |
Hillisch, Alexander |
2004 |
15 |
p. 659-669 11 p. |
artikel |
||
| 86 | Whatever happened to cassette-dosing pharmacokinetics? |
Manitpisitkul, Prasarn |
2004 |
15 |
p. 652-658 7 p. |
artikel |
||
| 87 | Who wants to be irrational? |
Lahana, Roger |
2003 |
15 |
p. 655-656 2 p. |
artikel |
87 gevonden resultaten